Heron Neutron Medical Corp
Heron Neutron Medical Corp develops and commercializes advanced medical equipment and technology, primarily focused on diagnostic and therapeutic solutions for healthcare providers.
Business. Heron Neutron Medical Corp (7799.TW) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is listed on the Taiwan Stock Exchange and specializes in the development and sale of advanced medical equipment. Specific details regarding its operating segments and geographic presence are not provided in the available data.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Heron Neutron Medical Corp (7799.TW) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is listed on the Taiwan Stock Exchange and specializes in the development and sale of advanced medical equipment. Specific details regarding its operating segments and geographic presence are not provided in the available data.
The company maintains a strong liquidity position, with cash and equivalents amounting to TWD 500 million, representing 4.3% of total assets. The price-to-book ratio of 4.57 and a current ratio of 162.91 indicate a highly liquid balance sheet with minimal leverage, as the debt-to-equity ratio is effectively zero. However, the company is experiencing negative operating cash flow of TWD -484.4 million and free cash flow of TWD -472.1 million, which suggests ongoing operational challenges.
Profitability metrics are negative, with a return on equity of -4.19% and a return on assets of -4.16%. The company reported a net loss of TWD -481.7 million for the period, with operating income at TWD -534.3 million and gross profit at TWD -25.8 million. These figures are significantly below the industry median for profitability metrics, indicating underperformance relative to peers.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of segment or geographic diversification increases exposure to sector-specific risks and limits visibility into potential growth drivers.
The company's revenue outlook is uncertain, with no disclosed growth trajectory in the provided data. Analysts have assigned a mean price target of TWD 1,175, significantly higher than the current market price of TWD 333, but the absence of disclosed revenue growth or margin improvement plans raises questions about the achievability of these targets.
Risk factors include the company's negative operating cash flow and free cash flow, which could pressure liquidity if sustained. The risk assessment indicates low dilution risk, with no immediate filing-based dilution flags detected. However, the absence of disclosed capital raising plans or dilution sources does not preclude future dilution if operational performance does not improve.
Recent events include the publication of the latest financial data, which shows continued losses and negative cash flows. No recent filings or transcripts were provided to indicate strategic shifts or operational improvements.
- The company has a highly liquid balance sheet but is experiencing significant operational cash outflows.
- Profitability metrics are negative and well below industry medians, indicating underperformance.
- Revenue is concentrated in a single segment with no geographic diversification disclosed.
- Analysts have assigned high price targets, but the absence of disclosed growth plans raises questions about their achievability.
- The company has low liquidity and dilution risk, but sustained negative cash flows could pressure liquidity.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -2,70 |
| Revenue | —no estimate | —no estimate | 32,0M TWD |
| Operating income | —no estimate | —no estimate | -410,6M TWD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Heron Neutron Medical Corp Market data — financials · 2026-05-27
- Heron Neutron Medical Corp Market data — analyst estimates · 2026-05-27